title: Unveiling the potential of prohibitin in cancer.
abstract: Recently, research has shed new light on the role of Prohibitin (PHB) in cancer pathogenesis across an array of cancer types. Important mechanisms for PHB have been unveiled in several cancers, especially with regard to the androgen independent state of prostate cancer (PC) and oestrogen dependent breast cancer. However, PHB is often overlooked due to its complex but subtle roles within the cell. Having gathered both historical and current research exploring PHB's role in different cancer types including prostate and breast, here we aim to pair this information with its molecular properties in the hope of translating this information into a clinical perspective, thus discussing its possible use in future cancer therapy.
authors.affiliation: Cardiff China Medical Research Collaborative (CCMRC), Cardiff University, School of Medicine, Henry Welcome Building, Heath Park, Cardiff CF14 4XN, UK. Electronic address: KoushyarS@cardiff.ac.uk.
authors.forename: Sarah
authors.initials: S
authors.lastname: Koushyar
authors.affiliation: Cardiff China Medical Research Collaborative (CCMRC), Cardiff University, School of Medicine, Henry Welcome Building, Heath Park, Cardiff CF14 4XN, UK.
authors.forename: Wen G
authors.initials: WG
authors.lastname: Jiang
authors.affiliation: Cardiff China Medical Research Collaborative (CCMRC), Cardiff University, School of Medicine, Henry Welcome Building, Heath Park, Cardiff CF14 4XN, UK.
authors.forename: D Alwyn
authors.initials: DA
authors.lastname: Dart
mesh_terms: D000970:Antineoplastic Agents / Q000378:metabolism*; D001943:Breast Neoplasms / Q000235:genetics*; D002453:Cell Cycle / Q000235:genetics*; D005260:Female; D006801:Humans; D008297:Male; D000091402:Prohibitins; D011471:Prostatic Neoplasms / Q000235:genetics*; D012097:Repressor Proteins / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; C000717328:PHB protein, human; D000091402:Prohibitins; D012097:Repressor Proteins
keywords: Breast cancer; Cancer therapy; Cell cycle; Prohibitin; Prostate cancer